UY38488A - Derivados de pirazol y su uso en medicina - Google Patents

Derivados de pirazol y su uso en medicina

Info

Publication number
UY38488A
UY38488A UY0001038488A UY38488A UY38488A UY 38488 A UY38488 A UY 38488A UY 0001038488 A UY0001038488 A UY 0001038488A UY 38488 A UY38488 A UY 38488A UY 38488 A UY38488 A UY 38488A
Authority
UY
Uruguay
Prior art keywords
medicine
modulators
derivatives
pirazole
tautomers
Prior art date
Application number
UY0001038488A
Other languages
English (en)
Inventor
Shawn Cabral
Ariamala Gopalsamy
Arjun Venkat Narayanan
Robinson, Jr
Casimiro-Garcia
Chulho Choi
David Hepworth
David Walter Piotrowski
Hatice Gizem Yayla
Jayasankar Jasti
Lee Richard Roberts
Lyn Howard Jones
Mihir Dineshkumar Parikh
Ming Zhu Chen
Olugbeminiyi Omezia Fadeyi
Robert Lee Dow
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY38488A publication Critical patent/UY38488A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con derivados de pirazol, con su uso en medicina, con composiciones que los contienen, con procesos para su preparación y con intermediarios utilizados en tales procesos. Más particularmente la invención se relaciona con moduladores de HbS de la Fórmula (I) o tautómeros de los mismos, o sales farmacéuticamente aceptables de los moduladores o tautómeros de los mismos, en donde X, Y, R2 y R3 son como se definen en la descripción. Los moduladores de HbS son potencialmente útiles en el tratamiento de un amplio margen de trastornos, que incluyen enfermedad de células falciformes (SCD).
UY0001038488A 2018-11-29 2019-11-27 Derivados de pirazol y su uso en medicina UY38488A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862772815P 2018-11-29 2018-11-29
US201962915784P 2019-10-16 2019-10-16

Publications (1)

Publication Number Publication Date
UY38488A true UY38488A (es) 2020-06-30

Family

ID=68807213

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038488A UY38488A (es) 2018-11-29 2019-11-27 Derivados de pirazol y su uso en medicina

Country Status (22)

Country Link
US (3) US11014908B2 (es)
EP (1) EP3886984A1 (es)
JP (1) JP2022510628A (es)
KR (1) KR20210097161A (es)
CN (1) CN113329789A (es)
AU (1) AU2019387290A1 (es)
BR (1) BR112021009057A2 (es)
CA (1) CA3121139A1 (es)
CO (1) CO2021006924A2 (es)
CR (1) CR20210284A (es)
CU (1) CU20210044A7 (es)
DO (1) DOP2021000103A (es)
EC (1) ECSP21037191A (es)
IL (1) IL283408A (es)
MA (1) MA54283A (es)
MX (1) MX2021006095A (es)
PE (1) PE20211592A1 (es)
PH (1) PH12021551035A1 (es)
SG (1) SG11202104585YA (es)
TW (2) TWI736037B (es)
UY (1) UY38488A (es)
WO (1) WO2020109994A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211592A1 (es) * 2018-11-29 2021-08-18 Pfizer Pirazoles como moduladores de la hemoglobina
US11597770B2 (en) 2020-01-24 2023-03-07 Pfizer Inc. Anti-E-selectin antibodies, compositions and methods of use
CN112079774A (zh) * 2020-10-17 2020-12-15 甘肃天后光学科技有限公司 软性隐形眼镜用蓝光吸收剂、其制备方法及应用方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
JP2007176799A (ja) 2005-12-27 2007-07-12 Sankyo Co Ltd 置換ベンゼン化合物を含有する医薬
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2011015524A2 (en) 2009-08-03 2011-02-10 Bayer Cropscience Ag Fungicide heterocycles derivatives
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
JP2013525476A (ja) * 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
JP5792819B2 (ja) 2010-09-14 2015-10-14 エクセリクシス， インク． Ｐｉ３ｋ−デルタの阻害剤ならびにそれらの使用法および製造法
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
PL2797416T3 (pl) 2011-12-28 2017-12-29 Global Blood Therapeutics, Inc. Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek
MY191087A (en) 2013-03-15 2022-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201591426A1 (ru) 2013-03-15 2016-02-29 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20151907A1 (es) 2013-03-15 2016-01-20 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR20190041548A (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US20140271591A1 (en) * 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9248199B2 (en) * 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
EP3157904B1 (en) 2014-06-20 2020-11-18 Institut Pasteur Korea Anti-infective compounds
WO2016043849A2 (en) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
EP3215514B1 (en) 2014-11-03 2018-11-21 F. Hoffmann-La Roche AG Bace1 inhibitors
EP3218380B1 (en) 2014-11-16 2021-03-17 Array Biopharma, Inc. Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
EP3472150A1 (en) 2016-06-17 2019-04-24 Fronthera U.S. Pharmaceuticals LLC Hemoglobin modifier compounds and uses thereof
WO2018035072A1 (en) 2016-08-15 2018-02-22 Purdue Research Foundation 4-substituted aminoisoquinoline derivatives
PE20211592A1 (es) * 2018-11-29 2021-08-18 Pfizer Pirazoles como moduladores de la hemoglobina

Also Published As

Publication number Publication date
TWI736037B (zh) 2021-08-11
PE20211592A1 (es) 2021-08-18
US11702405B2 (en) 2023-07-18
IL283408A (en) 2021-07-29
WO2020109994A1 (en) 2020-06-04
MX2021006095A (es) 2021-07-06
US11014908B2 (en) 2021-05-25
TW202033513A (zh) 2020-09-16
CU20210044A7 (es) 2022-01-13
JP2022510628A (ja) 2022-01-27
KR20210097161A (ko) 2021-08-06
US20220348555A1 (en) 2022-11-03
DOP2021000103A (es) 2021-07-30
ECSP21037191A (es) 2021-06-30
CA3121139A1 (en) 2020-06-04
BR112021009057A2 (pt) 2021-08-10
US20230382892A1 (en) 2023-11-30
US20200172512A1 (en) 2020-06-04
EP3886984A1 (en) 2021-10-06
CR20210284A (es) 2021-07-09
CN113329789A (zh) 2021-08-31
CO2021006924A2 (es) 2021-06-10
TW202140452A (zh) 2021-11-01
AU2019387290A1 (en) 2021-05-27
SG11202104585YA (en) 2021-06-29
PH12021551035A1 (en) 2021-12-06
MA54283A (fr) 2022-03-09

Similar Documents

Publication Publication Date Title
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
DOP2021000103A (es) Pirazoles como moduladores de hemoglobina
DOP2021000019A (es) Inhibidores de inflamasoma nlrp3
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2021002296A1 (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
NI201400031A (es) Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CO7160077A2 (es) Compuestos de pirazol sustituidos como antagonistas de lpar
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
CO2022008313A2 (es) Compuestos químicos
CL2019002601A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos.
CL2022003646A1 (es) Derivados de amidopirimidona
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
CO2024002844A2 (es) Compuestos espirocíclicos
CL2018002010A1 (es) Derivados de indano y su uso en terapias.
CL2020000439A1 (es) Sales de un compuesto y sus formas cristalinas.
EA202191162A1 (ru) Пиразолы в качестве модуляторов гемоглобина
CL2023000970A1 (es) Espiro derivados de alfa-d-galactopiranosidos
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos
CU20100094A7 (es) Derivados bis-(sulfonilamino) en terapia 066